Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- NEC Ventures into AI-Based Drug Discovery Biz
December 21, 2016
- Astellas’ DNA Vaccine for Peanut Allergy Granted FDA Fast-Track Status
December 21, 2016
- Tagrisso Logs Significant PFS Extension in Japanese NSCLC Patients
December 21, 2016
- Osteoporosis Med Romosozumab Filed in Japan for High-Risk Patients
December 21, 2016
- Nippon Shinyaku Gets Japan Rights to Danish Firm’s Iron Deficiency Med
December 21, 2016
- Teijin Pharma, Amgen Ink License Pact on Kidney Diseases
December 21, 2016
- New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
- Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
- AZ, NCC Ink Collaboration on Biomarkers for Lung Cancer Immunotherapy
December 20, 2016
- Hisamitsu Seeks Japan Approval for Allergic Rhinitis Tape Treatment
December 20, 2016
- Shionogi Hooks Up with Purdue on Naldemedine Commercialization in US
December 20, 2016
- Concerns Expressed Over High Cost of Regenerative Medicines; As with Opdivo, “Bound to Become Issue Again”
December 20, 2016
- Teva Takeda Recalls Dalteparin “Taiyo”
December 20, 2016
- Japan Osteoporosis Market to Expand 45.3% by 2024: Fuji Keizai
December 19, 2016
- Public Knowledge-Based Application Filed for Tamiflu’s New Pediatric Dosage
December 19, 2016
- Fujifilm Allies with Russia’s R-Pharm in Healthcare
December 19, 2016
- Otsuka Gets Exclusive Rights to Takara Bio’s Oncolytic Virus in Japan
December 16, 2016
- Continued Xtandi Treatment Fails to Extend PFS: US PIV Trial
December 16, 2016
- Belsomra Most Heavily Promoted Drug in HP Market October: Anterio
December 16, 2016
- Sysmex, Astellas, and Daiichi Sankyo Ink Memo to Create Method for Analyzing CTC
December 16, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…